4553 東和薬品

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	273,710	23,102	8.4%	28,079	10.3%	5,250	1.9%	106.66	5.4%	-0.6%	7.4%	-72.3%
2025/03	4Q	259,594	23,242	9.0%	26,152	10.1%	18,986	7.3%	385.71	13.9%	31.7%	6.8%	17.4%
2024/03	4Q	227,934	17,647	7.7%	24,477	10.7%	16,173	7.1%	328.59	9.1%	220.0%	376.1%	634.8%
2023/03	4Q	208,859	5,514	2.6%	5,141	2.5%	2,201	1.1%	44.72	26.1%	-71.3%	-77.4%	-86.2%
2022/03	4Q	165,615	19,205	11.6%	22,739	13.7%	15,914	9.6%	323.36	6.9%	-3.6%	21.7%	14.0%
2021/03	4Q	154,900	19,923	12.9%	18,677	12.1%	13,958	9.0%	283.62	40.3%	23.4%	-11.0%	-3.8%
2020/03	4Q	110,384	16,143	14.6%	20,990	19.0%	14,503	13.1%	294.74	5.0%	1.1%	11.3%	7.6%
2019/03	4Q	105,104	15,968	15.2%	18,865	17.9%	13,475	12.8%	273.85	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2026/03	4Q	273,710	23,102	8.4%	28,079	10.3%	5,250	1.9%	106.66	5.4%	-0.6%	7.4%	-72.3%
2025/03	4Q	259,594	23,242	9.0%	26,152	10.1%	18,986	7.3%	385.71	13.9%	31.7%	6.8%	17.4%
2024/03	4Q	227,934	17,647	7.7%	24,477	10.7%	16,173	7.1%	328.59	9.1%	220.0%	376.1%	634.8%
2023/03	4Q	208,859	5,514	2.6%	5,141	2.5%	2,201	1.1%	44.72	26.1%	-71.3%	-77.4%	-86.2%
2022/03	4Q	165,615	19,205	11.6%	22,739	13.7%	15,914	9.6%	323.36	6.9%	-3.6%	21.7%	14.0%
2021/03	4Q	154,900	19,923	12.9%	18,677	12.1%	13,958	9.0%	283.62	40.3%	23.4%	-11.0%	-3.8%
2020/03	4Q	110,384	16,143	14.6%	20,990	19.0%	14,503	13.1%	294.74	5.0%	1.1%	11.3%	7.6%
2019/03	4Q	105,104	15,968	15.2%	18,865	17.9%	13,475	12.8%	273.85	-	-	-	-